These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23706065)

  • 1. Novel routes to bipolar disorder drug discovery.
    Hoertel N; de Maricourt P; Gorwood P
    Expert Opin Drug Discov; 2013 Aug; 8(8):907-18. PubMed ID: 23706065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in drug target discovery in bipolar disorder.
    Alsaif M; Haenisch F; Guest PC; Rahmoune H; Bahn S
    Expert Opin Ther Targets; 2013 May; 17(5):565-77. PubMed ID: 23419165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic approaches for bipolar disorder drug discovery.
    Peedicayil J
    Expert Opin Drug Discov; 2014 Aug; 9(8):917-30. PubMed ID: 24875048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000.
    Sachs GS; Printz DJ; Kahn DA; Carpenter D; Docherty JP
    Postgrad Med; 2000 Apr; Spec No():1-104. PubMed ID: 10895797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs under early investigation for the treatment of bipolar disorder.
    Konstantakopoulos G; Dimitrakopoulos S; Michalopoulou PG
    Expert Opin Investig Drugs; 2015 Apr; 24(4):477-90. PubMed ID: 25704484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder.
    Kapczinski F; Frey BN; Kauer-Sant'Anna M; Grassi-Oliveira R
    Expert Rev Neurother; 2008 Jul; 8(7):1101-13. PubMed ID: 18590480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression?
    Soczynska JK; Kennedy SH; Goldstein BI; Lachowski A; Woldeyohannes HO; McIntyre RS
    Neurotoxicology; 2009 Jul; 30(4):497-521. PubMed ID: 19477018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bipolar disorder and complementary medicine: current evidence, safety issues, and clinical considerations.
    Sarris J; Lake J; Hoenders R
    J Altern Complement Med; 2011 Oct; 17(10):881-90. PubMed ID: 22010777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic use of omega-3 fatty acids in bipolar disorder.
    Balanzá-Martínez V; Fries GR; Colpo GD; Silveira PP; Portella AK; Tabarés-Seisdedos R; Kapczinski F
    Expert Rev Neurother; 2011 Jul; 11(7):1029-47. PubMed ID: 21721919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reproductive and metabolic abnormalities associated with bipolar disorder and its treatment.
    Kenna HA; Jiang B; Rasgon NL
    Harv Rev Psychiatry; 2009; 17(2):138-46. PubMed ID: 19373621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers.
    Gould TD; Quiroz JA; Singh J; Zarate CA; Manji HK
    Mol Psychiatry; 2004 Aug; 9(8):734-55. PubMed ID: 15136794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in bipolar disorder drug design toward the development of novel therapeutic targets: a clinician's perspective.
    Fornaro M; Kardash L; Novello S; Fusco A; Anastasia A; De Berardis D; Perna G; Carta MG
    Expert Opin Drug Discov; 2018 Mar; 13(3):221-228. PubMed ID: 29357703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative approaches to refractory depression in bipolar illness.
    Post RM; Leverich GS; Denicoff KD; Frye MA; Kimbrell TA; Dunn R
    Depress Anxiety; 1997; 5(4):175-89. PubMed ID: 9338110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapeutic targets for mood disorders.
    Machado-Vieira R; Salvadore G; DiazGranados N; Ibrahim L; Latov D; Wheeler-Castillo C; Baumann J; Henter ID; Zarate CA
    ScientificWorldJournal; 2010 Apr; 10():713-26. PubMed ID: 20419280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quetiapine monotherapy for bipolar depression.
    Janicak PG; Rado JT
    Expert Opin Pharmacother; 2011 Jul; 12(10):1643-51. PubMed ID: 21609188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future Directions for Pharmacotherapies for Treatment-resistant Bipolar Disorder.
    Dodd S; Fernandes BS; Dean OM
    Curr Neuropharmacol; 2015; 13(5):656-62. PubMed ID: 26467413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bipolar disorders and comorbid anxiety: prognostic impact and therapeutic challenges].
    Cazard F; Ferreri F
    Encephale; 2013 Feb; 39(1):66-74. PubMed ID: 23095585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinases as drug targets in the treatment of bipolar disorder.
    Catapano LA; Manji HK
    Drug Discov Today; 2008 Apr; 13(7-8):295-302. PubMed ID: 18405841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-canonical pathways in the pathophysiology and therapeutics of bipolar disorder.
    Machado-Vieira R; Courtes AC; Zarate CA; Henter ID; Manji HK
    Front Neurosci; 2023; 17():1228455. PubMed ID: 37592949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.